• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雾化 Ad5-nCoV 增强免疫在新冠灭活疫苗接种者中引发了强烈的免疫反应。

Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients.

机构信息

Beijing Institute of Biotechnology, Beijing, China.

Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China.

出版信息

Front Immunol. 2023 Oct 4;14:1239179. doi: 10.3389/fimmu.2023.1239179. eCollection 2023.

DOI:10.3389/fimmu.2023.1239179
PMID:37868993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10585368/
Abstract

INTRODUCTION

The SARS-CoV-2 Omicron variant has become the dominant SARS-CoV-2 variant and exhibits immune escape to current COVID-19 vaccines, the further boosting strategies are required.

METHODS

We have conducted a non-randomized, open-label and parallel-controlled phase 4 trial to evaluate the magnitude and longevity of immune responses to booster vaccination with intramuscular adenovirus vectored vaccine (Ad5-nCoV), aerosolized Ad5-nCoV, a recombinant protein subunit vaccine (ZF2001) or homologous inactivated vaccine (CoronaVac) in those who received two doses of inactivated COVID-19 vaccines.

RESULTS

The aerosolized Ad5-nCoV induced the most robust and long-lasting neutralizing activity against Omicron variant and IFNg T-cell response among all the boosters, with a distinct mucosal immune response. SARS-CoV-2-specific mucosal IgA response was substantially generated in subjects boosted with the aerosolized Ad5-nCoV at day 14 post-vaccination. At month 6, participants boosted with the aerosolized Ad5-nCoV had remarkably higher median titer and seroconversion of the Omicron BA.4/5-specific neutralizing antibody than those who received other boosters.

DISCUSSION

Our findings suggest that aerosolized Ad5-nCoV may provide an efficient alternative in response to the spread of the Omicron BA.4/5 variant.

CLINICAL TRIAL REGISTRATION

https://www.chictr.org.cn/showproj.html?proj=152729, identifier ChiCTR2200057278.

摘要

简介

SARS-CoV-2 的奥密克戎变体已成为主要的 SARS-CoV-2 变体，并对当前的 COVID-19 疫苗表现出免疫逃逸，因此需要进一步的增强策略。

方法

我们进行了一项非随机、开放性、平行对照的 4 期试验，以评估肌肉内腺病毒载体疫苗（Ad5-nCoV）、雾化 Ad5-nCoV、重组蛋白亚单位疫苗（ZF2001）或同源灭活疫苗（CoronaVac）作为加强针在接种两剂灭活 COVID-19 疫苗的人群中引起的免疫反应的幅度和持久性。

结果

雾化 Ad5-nCoV 在所有加强针中诱导了针对奥密克戎变体的最强大和最持久的中和活性以及 IFNγ T 细胞反应，并具有明显的粘膜免疫反应。在接种雾化 Ad5-nCoV 后的第 14 天，受试者中产生了大量的 SARS-CoV-2 特异性粘膜 IgA 反应。在 6 个月时，与接受其他加强针的参与者相比，接受雾化 Ad5-nCoV 加强针的参与者对奥密克戎 BA.4/5 特异性中和抗体的中位滴度和血清转化率显著更高。

讨论

我们的研究结果表明，雾化 Ad5-nCoV 可能是应对奥密克戎 BA.4/5 变体传播的有效替代方案。

临床试验注册

https://www.chictr.org.cn/showproj.html?proj=152729，标识符 ChiCTR2200057278。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/0b1d2d2465f1/fimmu-14-1239179-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/16a0c6871d67/fimmu-14-1239179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/f79d32c909a2/fimmu-14-1239179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/8bd2b86b57e0/fimmu-14-1239179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/de2d54326cd7/fimmu-14-1239179-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/0644013520fb/fimmu-14-1239179-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/0b1d2d2465f1/fimmu-14-1239179-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/16a0c6871d67/fimmu-14-1239179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/f79d32c909a2/fimmu-14-1239179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/8bd2b86b57e0/fimmu-14-1239179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/de2d54326cd7/fimmu-14-1239179-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/0644013520fb/fimmu-14-1239179-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c385/10585368/0b1d2d2465f1/fimmu-14-1239179-g006.jpg

相似文献

1
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients.雾化 Ad5-nCoV 增强免疫在新冠灭活疫苗接种者中引发了强烈的免疫反应。
Front Immunol. 2023 Oct 4;14:1239179. doi: 10.3389/fimmu.2023.1239179. eCollection 2023.
2
Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.与注射用和雾化用 Ad5-nCoV 加强针和 BA.2 感染相关的中和抗体水平。
BMC Med. 2023 Jul 3;21(1):233. doi: 10.1186/s12916-023-02942-3.
3
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.18 岁及以上成年人中口服雾化双价腺病毒 5 型载体 COVID-19 疫苗和 B.1.1.529 变异腺病毒 5 型载体 COVID-19 疫苗异源加强免疫的安全性和免疫原性：一项随机、双盲、平行对照试验。
Emerg Microbes Infect. 2024 Dec;13(1):2281355. doi: 10.1080/22221751.2023.2281355. Epub 2023 Dec 30.
4
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.腺病毒载体二价疫苗在小鼠模型中对野生型 SARS-CoV-2 和奥密克戎变异株的免疫原性。
Vaccine. 2024 Feb 27;42(6):1292-1299. doi: 10.1016/j.vaccine.2024.01.073. Epub 2024 Jan 30.
5
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.成年人接种同源和异源加强疫苗后的免疫反应和转录谱。
Front Immunol. 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024.
6
Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.三剂灭活 SARS-CoV-2 疫苗基础免疫后接种 Ad5-nCoV 的安全性和免疫原性：中国成年人的研究。
Nat Commun. 2023 Aug 8;14(1):4757. doi: 10.1038/s41467-023-40489-2.
7
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.三剂科兴疫苗后，雾化腺病毒载体5型新冠疫苗、肌肉注射腺病毒载体5型新冠疫苗或灭活新冠疫苗科兴疫苗作为第二剂加强针的安全性和免疫原性：一项多中心、开放标签、4期随机试验。
Lancet Respir Med. 2023 Jul;11(7):613-623. doi: 10.1016/S2213-2600(23)00049-8. Epub 2023 Mar 7.
8
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.在接种两剂灭活 COVID-19 疫苗的成年人中，使用雾化型 Ad5-nCoV 进行异源加强免疫的安全性、免疫原性和保护效果：一项多中心、开放性 3 期临床试验。
Lancet Infect Dis. 2023 Oct;23(10):1143-1152. doi: 10.1016/S1473-3099(23)00350-X. Epub 2023 Jun 20.
9
Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.在三剂灭活疫苗后作为第四剂加强针接种的mRNA新冠疫苗（RQ3013）的安全性、免疫原性和有效性：一项双盲、随机、对照的3b期试验。
EClinicalMedicine. 2023 Sep 21;64:102231. doi: 10.1016/j.eclinm.2023.102231. eCollection 2023 Oct.
10
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗（Ad5-nCoV）在成年人中的安全性、耐受性和免疫原性：一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.

引用本文的文献

1
Immunogenicity, Safety, and Protective Efficacy of Mucosal Vaccines Against Respiratory Infectious Diseases: A Systematic Review and Meta-Analysis.黏膜疫苗对呼吸道传染病的免疫原性、安全性及保护效力：一项系统评价与Meta分析
Vaccines (Basel). 2025 Jul 31;13(8):825. doi: 10.3390/vaccines13080825.
2
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.雾化腺病毒载体新冠疫苗和肌肉注射mRNA疫苗二价加强针的安全性和免疫原性：一项随机开放标签临床试验。
Nat Commun. 2025 Aug 7;16(1):7281. doi: 10.1038/s41467-025-62698-7.
3

本文引用的文献

1
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
2
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.SARS-CoV-2 特异性鼻内 IgA 在 COVID-19 住院治疗 9 个月后消失，且不会因后续接种疫苗而产生。
EBioMedicine. 2023 Jan;87:104402. doi: 10.1016/j.ebiom.2022.104402. Epub 2022 Dec 19.
3
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.
Developing the next-generation of adenoviral vector vaccines.
开发下一代腺病毒载体疫苗。
Hum Vaccin Immunother. 2025 Dec;21(1):2514356. doi: 10.1080/21645515.2025.2514356. Epub 2025 Jul 1.
4
Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice.自组装Toll样受体2（TLR2）激动剂可促进小鼠黏膜免疫反应，且不会造成肺部免疫病理损伤。
NPJ Vaccines. 2025 Jun 18;10(1):127. doi: 10.1038/s41541-025-01185-y.
5
An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.一种鼻内亚单位疫苗在小鼠模型中诱导针对呼吸道病毒的保护性全身和黏膜抗体免疫。
Nat Commun. 2025 May 1;16(1):3999. doi: 10.1038/s41467-025-59353-6.
6
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China.成人中雾化或肌内注射5型腺病毒载体新冠病毒疫苗加强剂量的有效性：中国一项多中心、部分随机、平台试验
Nat Commun. 2025 Mar 26;16(1):2969. doi: 10.1038/s41467-025-58327-y.
7
Reduced SARS-CoV-2 Infection Rates in Lab Workers Conducting Nucleic Acid Testing: Controlling for the Healthy Worker Effect.从事核酸检测的实验室工作人员中新冠病毒感染率降低：对健康工人效应的控制
J Epidemiol Glob Health. 2025 Jan 29;15(1):10. doi: 10.1007/s44197-025-00343-8.
8
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.抗新冠病毒疫苗最新情况及防范新型严重急性呼吸综合征冠状病毒2变种的挑战
Pathogens. 2025 Jan 1;14(1):23. doi: 10.3390/pathogens14010023.
AZD1222（ChAdOx1 nCoV-19）新冠疫苗在 6 个月以上的保护持久性和免疫原性。
J Clin Invest. 2022 Sep 15;132(18):e160565. doi: 10.1172/JCI160565.
4
Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.接种 BNT162b2 疫苗的老年人对 21 种 SARS-CoV-2 变异体的中和抗体活性。
Nat Microbiol. 2022 Aug;7(8):1180-1188. doi: 10.1038/s41564-022-01163-3. Epub 2022 Jul 14.
5
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.SARS-CoV-2 奥密克戎亚变种 BA.2.12.1、BA.4 和 BA.5 的抗体逃逸
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
6
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.中国成年人接种 SARS-CoV-2 BNT162b1 mRNA 疫苗后的免疫持久性和安全性：一项随机、安慰剂对照、双盲 1 期临床试验。
Adv Ther. 2022 Aug;39(8):3789-3798. doi: 10.1007/s12325-022-02206-1. Epub 2022 Jun 30.
7
Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.开发针对包含奥密克戎的 SARS-CoV-2 变异株的假病毒中和测定法。
Viruses. 2022 Jun 18;14(6):1332. doi: 10.3390/v14061332.
8
Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.接种 2 剂灭活疫苗成年人接种第三剂 BNT162b2 对原始严重急性呼吸综合征冠状病毒 2 和奥密克戎变异株的免疫原性。
Clin Infect Dis. 2023 Feb 8;76(3):e299-e307. doi: 10.1093/cid/ciac458.
9
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.两剂灭活 SARS-CoV-2 疫苗初免后，用口服雾化 Ad5-nCoV 进行异源加强免疫在中国成年人中的安全性和免疫原性：一项随机、开放标签、单中心试验。
Lancet Respir Med. 2022 Aug;10(8):739-748. doi: 10.1016/S2213-2600(22)00087-X. Epub 2022 May 20.
10
Immune recall improves antibody durability and breadth to SARS-CoV-2 variants.免疫回忆可提高针对 SARS-CoV-2 变异株的抗体持久性和广谱性。
Sci Immunol. 2022 Dec 23;7(78):eabp8328. doi: 10.1126/sciimmunol.abp8328. Epub 2022 Dec 16.